Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 16;34(29):9665–9676. doi: 10.1523/JNEUROSCI.4220-13.2014

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Klampfl et al.

This article is freely available online through the J Neurosci Author Open Choice option.

PMC Copyright notice

Figure 4. — Effect of intra-mpBNST CRF-R1 or CRF-R2 specific agonist (ago) or antagonist (ant) treatment on maternal care of lactating dams under nonstress conditions on LD1 (A) and stress conditions on LD5 (B). ABN (top) and sum of nursing (bottom) were scored for 60 min before and for 90 min after infusion (A) or 60 min after maternal defense (B). Under nonstress conditions, ABN and nursing were also observed for additional 60 min in the afternoon (A). Dams received an acute bilateral infusion of VEH (5 μl of sterile Ringer's solution; pH 7.4), CRF-R1 agonist human/rat CRF (CRF-R1 ago; 1 μg/0.5 μl), CRF-R1 antagonist CP-154,526 (CRF-R1 ant; 12 μg/0.5 μl), CRF-R2 agonist stresscopin (CRF-R2 ago; 3 μg/0.5 μl), or CRF-R2 antagonist Astressin-2B (CRF-R2 ant; 4 μg/0.5 μl) into the mpBNST. Data are presented as mean + SEM. n = 8–14 per group. **p ≤ 0.01, *p ≤ 0.05 versus VEH (two-way ANOVA for repeated measures; factors: time × treatment); +p ≤ 0.05, (+) p = 0.08 versus t −100 min (one-way ANOVA for repeated measures; factor: time).